What AI says about CASGEVY
CASGEVY is a one-time gene edited therapy designed to treat specific conditions.
AI mentioned CASGEVY from October 2025 to July 2026.
Questions and answers
- AI picks most
- What are the latest affordable advancements in biopharma for treating rare diseases?AI picks U.S. Food and Drug Administration (FDA) and 6 more about as often
Excerpts where CASGEVY appeared in the AI's answer
Google AI ModeJul 20, 2026, Google AI Mode The FDA has approved Casgevy (vertexpharma.com) , the first CRISPR-based gene-editing therapy for sickle cell disease
ChatGPTJul 4, 2026, ChatGPT For example, the U.S. recently expanded approval of Casgevy to younger children with inherited blood disorders, allowing earlier treatment for eligible patients.
CASGEVY in AI answers
What are the latest affordable advancements in biopharma for treating rare diseases?
ChatGPTChatGPT· Jul 4, 2026
For example, the U.S. recently expanded approval of Casgevy to younger children with inherited blood disorders, allowing earlier treatment for eligible patients.
Google AI ModeGoogle AI Mode· Jul 20, 2026
The FDA has approved Casgevy (vertexpharma.com) , the first CRISPR-based gene-editing therapy for sickle cell disease
Sites AI cites
None of these answers cited casgevy.com. AI cited pmc.ncbi.nlm.nih.gov, reuters.com, and phrma.org.
Brands AI mentions
AI mentioned CASGEVY most often alongside PaVe-GT, Cell and Gene Therapy (CGT) Access Model, and Deerfield Management.
